Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
15 Leser
Artikel bewerten:
(0)

Regulatory Affairs Outsourcing Market - Expected to Reach $12.4 Billion by 2025

DUBLIN, Dec. 27, 2017 /PRNewswire/ --

The "Regulatory Affairs Outsourcing Market Analysis by Service (Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Application) and Segment Forecasts, 2014 - 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global regulatory affairs outsourcing market is expected to reach USD 12.4 billion by 2025. Outsourcing of regulatory affairs functions to CROs or other individual service providers offers life science companies the benefit to achieve cost efficiency and reduce the overall approval process time by eliminating delays associated with regulatory submission requirements. These benefits are primarily driving the outsourcing trend and hence impacting the market over the forecast period.

The augmenting disease prevalence in Asia Pacific and MEA regions and increasing number of clinical trials being conducted is stimulating life science companies to expand into these regions thereby increasing the demand of these services. Changing regulatory landscape especially in developing regions and stringent directive requirements in developed regions such as North America and Europe are driving the adoption of outsourcing trend in regulatory affairs function. Growth in emerging areas such as biosimilars and orphan drug is expected to stimulate the demand for regulatory expertise thereby contributing to the growth of regulatory affairs outsourcing market.

Further Key Findings From The Study Suggest:

  • Based on product, legal representation is expected to witness lucrative growth during the forecast period owing to healthcare reforms especially in emerging regions such as India and China. Also, rising demand of legal representation in regions such as Europe for gaining market authorization for companies who do not have an established base in the region. For instance, small or mid-size biopharmaceutical companies having domestic only, requires legal representative if they want to expand their presence in European countries such as UK and Germany. Regulatory writing and publishing is expected to be the leading segment during the forecast period.
  • Few of the industry players for the regulatory affairs outsourcing market are Clinical Research, Clinilabs Inc., Criterium Inc., PRA International, Promedica International, Wuxi AppTec, Medpace Inc.The other major players include Pharmaceutical Product Development(PPD), PAREXEL International Corporation, Charles River Laboratories International Inc., and Covance Inc.
  • There has been a trend of strategic partnership between services providers for increasing service portfolio or expanding regional presence. For instance, PPD formed a joint venture with Shin Nippon Biomedical Laboratories Ltd. (SNBL), leading provider of development services to biopharmaceuticals, to provide clinical development services in Japan including function based services such as regulatory and pharmacovigilance.

Key Topics Covered:

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Regulatory Affairs Outsourcing Industry Outlook

Chapter 4. Regulatory Affairs Outsourcing Service Outlook

Chapter 5. Regulatory Affairs Outsourcing Regional Outlook

Chapter 6 Competitive Landscape

  • Accell Clinical Research
  • Genpact Ltd
  • Criterium, Inc
  • PRA Health Sciences, Inc
  • Promedica International
  • Wuxi AppTec
  • Medpace, Inc
  • Pharmaceutical Product Development (PPD), LLC
  • ARAXEL International Corporation
  • Charles River Laboratories International, Inc
  • ICON Plc
  • QuintilesIMS
  • Covance, Inc


For more information about this report visit https://www.researchandmarkets.com/research/gwpcld/regulatory

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.